GEN Exclusives

More »

GEN News Highlights

More »
Jun 8, 2012

Sorrento Wins $600K to Develop MRSA Antibodies that Disrupt Quorum Sensing

  • Sorrento Therapeutics received a two-year, $600,000 Advanced Technology Small Business Technology (STTR) fast-track grant from the National Institute of Allergy and Infectious Diseases (NIAID) to support development of human antibody therapeutics against Staphylococcus aureus infections, including MRSA. The Phase I grant may subsequently be followed by Phase II funding of $1 million a year for another two years.

    Sorrento is exploiting its STI antibody library platform both through technology access agreements and through the in-house discovery and development of antibody therapeutics against cancer, inflammation, metabolic diseases, and infectious diseases. Lead MRSA program STI-001 is based on STI antibodies targeting bacterial auto-inducing peptides (AIPs) involved in quorum sensing, a bacterial communication process that is central to virulence.

    The program hinges on quorum quenching IP licensed from The Scripps Research Institute in 2010. The same year, Sorrento received an initial Phase I grant to support the development of a Staphylococcal vaccine that targets AIPs. In July 2011 the firm received another $600,000, two-year STTR grant from NIAID to support the development of anti-AIP therapeutics and vaccines against Clostridium difficile.

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?